Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

Original publication




Journal article


Clin Transl Radiat Oncol

Publication Date





61 - 66


ATM, Ataxia telangiectasia mutated, ATR, Ataxia telangiectasia and Rad3 related, CRT, Chemoradiotherapy, CT, Computed tomography, CTCAE, Common terminology criteria for adverse events, CTRad, Clinical and Translational Radiotherapy Research Working Group, Continual reassessment method, DDRi, DNA damage response inhibitor, DLT, Dose limiting toxicity, DNA damage repair inhibitor, DNA, Deoxyribonucleic acid, DNA-PK, DNA-dependent protein kinase, ECOG, Eastern Cooperative Oncology Group, EORTC, European Organisation for Research and Treatment of Cancer, ICRU, International Commission on Radiation Units and Measurements, IMPs, Investigational medicinal products, LA, Locally advanced, MRC, Medical Research Council, NCRI, National Cancer Research Institute, NSCLC, Non-small cell lung cancer, Non-small cell lung cancer, PARP, Poly (ADP-ribose) polymerase, PET, Positron emission tomography, PFS, Progression free survival, PROMs, Patient-reported outcome measures, Platform trial, RECIST, Response evaluation criteria in solid tumours, RP2D, Recommended phase II dose, RT, Radiotherapy, SACT, Systemic anti-cancer therapy, SRC, Safety review committee, Sequential chemoradiotherapy, TNM, Tumour node metastasis, TiTE-CRM, Time to event continual reassessment method, cfDNA, Cell-free DNA